family with sequence similarity 229 member AGenealiases: []
Q-omics provides the consensus-scored FAM229A profile across patient tissues and cancer cell-line models. FAM229A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM229A is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, FAM229A RNA expression shows 18,854 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where FAM229A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM229A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM229A survival associations across molecular data types. FAM229A RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM229A RNA expression–survival associations across cancer types. High FAM229A expression shows unfavorable associations in ACC, KIRC, COAD and DLBC, but favorable associations in BLCA and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM229A RNA expression.
This table summarizes FAM229A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for FAM229A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM229A shows lower tumor expression in KICH and BRCA and higher tumor expression in LIHC, COAD, BLCA and HNSC. The KICH box plot shows higher FAM229A RNA expression in normal versus tumor tissue (log2 FC = −0.975, t-test p < 0.001).
This table shows molecular features associated with FAM229A in patient tissues and cancer cell lines. In patient samples, FAM229A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM229A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SOFT_TISSUE.
